Clavis Pharma ASA
Oncology Drugs Company
Website
www.clavispharma.com
Contact Name
Mr. Geir Christian Melen
Company Position
Chief Executive Officer
Contact Email
mail@clavispharma.com
Contact Address
Head Office
Parkveien 53B
NO-0256 Oslo
Norway
Contact Phone
+47 24 11 09 50
Latest News
24th November 2009
Clavis Pharma ASA and newly formed Clovis Oncology, Inc. have announced a $380 million partnership for the development and commercialisation of Clavis Pharma’s novel, patented, drug candidate CP-4126
Read this article
More News
16th March 2009
Clavis Pharma ASA announces positive results from a second interim analysis of the elacytarabine (CP-4055) Phase II study in patients with late stage acute myeloid leukaemia (AML).
Read this article
11th February 2008
Clavis Pharma announced today that an important milestone has been reached in its haematology program with ELACYT™.
Read this article
20th September 2007
Clavis Pharma has announced that the European Commission has granted orphan drug designation to ELACYT (TM) for the treatment of Acute Myeloid Leukaemia.
Read this article
Clavis Pharma ASA is a drug discovery and development company utilising its proprietary Lipid Vector Technology to develop small molecule pharmaceuticals. Clavis Pharma has developed drug candidates within oncology, viral and inflammatory diseases. The Company has three programmes in clinical and pre-clinical development. The business scope is to develop the drug candidates through clinical feasibility studies and to partner with larger pharmaceutical companies for late stage development, marketing and sales.
Clavis Pharma listed on the Oslo Børs Stock Exchange in 2006. (CLAVIS.OL)
